Abstract
To study novel treatments for high grade gliomas (WHO grade III and IV) we need animal models of those disorders. Orthotopic tumors in mouse or rats seem at present the most reliable in vivo glioma model in order to develop specific therapies. The orthotopic tumor characteristics should yet closely mimic the human glioma features (in particular infiltrating growth and neovascularization). In this regard, glioma cell lines with stem properties (glioma stem cells – GSC) may fulfill at best those needs. Orthotopic gliomas developed from some widely used, established non-stem cell lines showing poor infiltrating capacity are not suitable. Therapeutic and diagnostic procedures recently developed using orthotopic rodent glioma tumors along their potentialities and pitfalls are analyzed.
Keywords: Brain tumor, radiotherapy, temozolomide, glioblastoma, cell cycle, resistance and in vivo.
Current Medicinal Chemistry
Title:Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models
Volume: 20 Issue: 26
Author(s): Guido Frosina
Affiliation:
Keywords: Brain tumor, radiotherapy, temozolomide, glioblastoma, cell cycle, resistance and in vivo.
Abstract: To study novel treatments for high grade gliomas (WHO grade III and IV) we need animal models of those disorders. Orthotopic tumors in mouse or rats seem at present the most reliable in vivo glioma model in order to develop specific therapies. The orthotopic tumor characteristics should yet closely mimic the human glioma features (in particular infiltrating growth and neovascularization). In this regard, glioma cell lines with stem properties (glioma stem cells – GSC) may fulfill at best those needs. Orthotopic gliomas developed from some widely used, established non-stem cell lines showing poor infiltrating capacity are not suitable. Therapeutic and diagnostic procedures recently developed using orthotopic rodent glioma tumors along their potentialities and pitfalls are analyzed.
Export Options
About this article
Cite this article as:
Frosina Guido, Development of Therapeutics for High Grade Gliomas Using Orthotopic Rodent Models, Current Medicinal Chemistry 2013; 20 (26) . https://dx.doi.org/10.2174/0929867311320260011
DOI https://dx.doi.org/10.2174/0929867311320260011 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme
Current Pharmaceutical Design Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Elevated Levels of Bilirubin and Long-Term Exposure Impair Human Brain Microvascular Endothelial Cell Integrity
Current Neurovascular Research Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Aneurysm of the Communicating Vein Between the Left Renal Vein and Left Ascending Lumbar Vein Mimicking Retroperitoneal Lymphadenopathy: A Case Report
Current Medical Imaging Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Current Molecular Medicine